CAMBRIDGE, Mass., Sept. 3,
2024 /PRNewswire/ -- NeuroBo Pharmaceuticals,
Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused
on transforming cardiometabolic diseases, today announced that
Hyung Heon Kim, President and Chief
Executive Officer and Marshall H.
Woodworth, Chief Financial Officer, will present a company
overview on Tuesday, September 10, at
1:30 pm ET, during the H.C.
Wainwright 26th Annual Global Investment Conference taking place
September 9-11, 2024, in New York.
Management will also be available for one-on-one meetings during
the event. Institutional investors who would like to listen to the
Company's presentation or request a meeting can do so after
registering for the conference at
www.hcwevents.com/annualconference. To schedule a meeting with
management outside of the conference, investors can contact
Michael Miller at
mmiller@rxir.com.
About NeuroBo Pharmaceuticals
NeuroBo
Pharmaceuticals, Inc. is a clinical-stage biotechnology company
focused on transforming cardiometabolic diseases. The company is
currently developing DA-1726 for the treatment of obesity, and is
developing DA-1241 for the treatment of Metabolic
Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel
oxyntomodulin (OXM) analogue that functions as a glucagon-like
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual
agonist. OXM is a naturally-occurring gut hormone that activates
GLP1R and GCGR, thereby decreasing food intake while increasing
energy expenditure, thus potentially resulting in superior body
weight loss compared to selective GLP1R agonists. DA-1241 is a
novel G-protein-coupled receptor 119 (GPR119) agonist that promotes
the release of key gut peptides GLP-1, GIP, and PYY. In
pre-clinical studies, DA-1241 demonstrated a positive effect on
liver inflammation, lipid metabolism, weight loss, and glucose
metabolism, reducing hepatic steatosis, hepatic inflammation, and
liver fibrosis, while also improving glucose control.
For more information, please visit www.neurobopharma.com.
Contacts:
NeuroBo Pharmaceuticals, Inc.
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@neurobopharma.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:https://www.prnewswire.com/news-releases/neurobo-to-participate-in-the-hc-wainwright-26th-annual-global-investment-conference-302236111.html
SOURCE NeuroBo Pharmaceuticals, Inc.